Followers | 504 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Thursday, December 17, 2015 1:30:59 PM
bullish optionable 57.74
## source: finance.yahoo.com
Thu, 17 Dec 2015 12:16:19 GMT ~ Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
[at noodls] - , /PRNewswire/ -- (NASDAQ: ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTR in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, ...
read full: http://www.noodls.com/view/2C73D896231DF920130FF75F1B9E99BDAA397641
*********************************************************
Thu, 17 Dec 2015 12:01:00 GMT ~ 7:01 am ISIS Pharm initiates an investigator-sponsored phase 2 study of ISIS-TTR Rx in patients w/ TTR Cardiomyopathy Amyloidosis
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#isis
*********************************************************
Thu, 17 Dec 2015 12:00:00 GMT ~ Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis
[PR Newswire] - CARLSBAD, Calif., Dec. 17, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (ISIS) announced today the initiation of an investigator-sponsored, open-label Phase 2 study evaluating ISIS-TTRRx in patients with wild-type transthyretin amyloidosis (wt-TTR amyloidosis, previously referred to as senile systemic amyloidosis, or SSA). The Phase 2 study will be conducted by Dr. Rodney Falk, the director of the Cardiac Amyloidosis Program and a cardiovascular medicine specialist at the Brigham and Women's Hospital in Boston. The Phase 2, investigator-initiated study will evaluate treatment with ISIS-TTRRx in approximately 50 patients with wt-TTR amyloidosis. Patients must have evidence of cardiac disease as indicated by an interventricular septum thickness (IVS) of >1.3cm with a positive cardiac biopsy. The effects of ISIS-TTRRx on cardiac disease stabilization will be measured by cardiac imaging at 6, 12 and 18 months. Data from this study will provide additional information on ISIS-TTRRx and can also be included in the robust data package Isis and GSK are generating to support regulatory filings for ISIS-TTRRx in all patients with TTR amyloidosis. For further study information, please visit www.clinicaltrials.gov and search for ISIS-TTRRx.
read full: http://finance.yahoo.com/news/isis-pharmaceuticals-announces-initiation-investigator-120000353.html
*********************************************************
Tue, 15 Dec 2015 14:01:58 GMT ~ Isis Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 15, 2015
read full: http://www.capitalcube.com/blog/index.php/isis-pharmaceuticals-inc-breached-its-50-day-moving-average-in-a-bearish-manner-december-15-2015/
*********************************************************
Tue, 15 Dec 2015 01:40:00 GMT ~ Will 2016 Be Alnylam Pharmaceuticals, Inc.'s Best Year Yet?
read full: http://www.fool.com/investing/general/2015/12/14/will-2016-be-alnylam-pharmaceuticals-incs-best-yea.aspx?source=eogyholnk0000001&utm_source=yahoo&utm_medium=feed&utm_campaign=article
*********************************************************
$ISIS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ISIS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ISIS/company-info
Ticker: $ISIS
OTC Market Place: Not Available
CIK code: 0000874015
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
Incorporated In: DE, USA
$ISIS share structure
## source: otcmarkets.com
Market Value: $7,130,187,147 a/o Dec 16, 2015
Shares Outstanding: 120,117,708 a/o Nov 04, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$ISIS extra dd links
Company name: Isis Pharmaceuticals, Inc.
Company website: http://www.isip.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=ISIS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=ISIS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=ISIS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/news - http://finance.yahoo.com/q/h?s=ISIS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/ISIS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=ISIS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/ISIS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Isis+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Isis+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Isis+Pharmaceuticals%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.isip.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.isip.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.isip.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/ISIS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000874015&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=ISIS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=ISIS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=ISIS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=ISIS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=ISIS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=ISIS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=ISIS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/ISIS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=ISIS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/ISIS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=ISIS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/ISIS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/ISIS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/ISIS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/ISIS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/ISIS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=ISIS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=ISIS
$ISIS DD Notes ~ http://www.ddnotesmaker.com/ISIS
Recent IONS News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/10/2024 09:19:04 PM
- Ionis announces pricing of $500.3 million public offering • PR Newswire (US) • 09/10/2024 01:10:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:33:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/09/2024 08:23:39 PM
- Ionis announces proposed public offering of common stock • PR Newswire (US) • 09/09/2024 08:20:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:51:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:43:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:43:19 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:41:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:40:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:40:55 AM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 09/05/2024 01:33:46 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM